BofA downgraded PepGen (PEPG) to Underperform from Neutral with a $3 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on PEPG: FDA issues clinical hold notice to PepGen on IND app for CONNECT2-EDO51 trial Two new option listings and one option delisting on November 21st PepGen price target lowered to $6 from $10 at BofA PepGen reports Q3 EPS (66c), consensus (87c)
